JPS6333103B2 - - Google Patents
Info
- Publication number
- JPS6333103B2 JPS6333103B2 JP54080741A JP8074179A JPS6333103B2 JP S6333103 B2 JPS6333103 B2 JP S6333103B2 JP 54080741 A JP54080741 A JP 54080741A JP 8074179 A JP8074179 A JP 8074179A JP S6333103 B2 JPS6333103 B2 JP S6333103B2
- Authority
- JP
- Japan
- Prior art keywords
- erythropoietin
- latex
- sensitized
- sensitized latex
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000004816 latex Substances 0.000 claims description 60
- 229920000126 latex Polymers 0.000 claims description 60
- 239000002245 particle Substances 0.000 claims description 25
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000004471 Glycine Substances 0.000 claims description 6
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims description 5
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims description 5
- 102000044890 human EPO Human genes 0.000 claims description 5
- 229920002307 Dextran Polymers 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 230000005484 gravity Effects 0.000 claims description 3
- 229940105423 erythropoietin Drugs 0.000 description 68
- 102000003951 Erythropoietin Human genes 0.000 description 55
- 108090000394 Erythropoietin Proteins 0.000 description 55
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 55
- 210000003743 erythrocyte Anatomy 0.000 description 16
- 210000001124 body fluid Anatomy 0.000 description 15
- 239000010839 body fluid Substances 0.000 description 15
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 208000007502 anemia Diseases 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 239000005995 Aluminium silicate Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000004520 agglutination Effects 0.000 description 6
- 235000012211 aluminium silicate Nutrition 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229920003048 styrene butadiene rubber Polymers 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102000014702 Haptoglobin Human genes 0.000 description 1
- 108050005077 Haptoglobin Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- MYRTYDVEIRVNKP-UHFFFAOYSA-N divinylbenzene Substances C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- BLCTWBJQROOONQ-UHFFFAOYSA-N ethenyl prop-2-enoate Chemical compound C=COC(=O)C=C BLCTWBJQROOONQ-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- 230000001096 hypoplastic effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002102 polyvinyl toluene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- -1 sodium nitride Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/746—Erythropoetin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
æ¬çºæã¯ãããšãªã¹ãããšãã³æäœã©ããã¯ã¹
ã«é¢ãããããã«è©³ããã¯ãããã®ç²Ÿè£œãšãªã¹ã
ããšãã³ãæäœããããšãªã¹ãããšãã³æäœã©ã
ãã¯ã¹ç²åãå«æããæäœã©ããã¯ã¹ããã³ãã
ã«å®å®å€ãå«æãããšãªã¹ãããšãã³æäœã©ãã
ã¯ã¹ã«é¢ããã ããã®èµ€è¡çã®å¯¿åœã¯çŽ120æ¥ã§ãããæ¯æ¥å š
èµ€è¡çã®1/120ã现網å ç®ç³»ã§ç Žå£ãããããå
æã«åãæ°ã®èµ€è¡çãç£çãããŠåžžã«äžå®ã®èµ€è¡
çæ°ãä¿ãããŠããã èµ€è¡çã¯ã骚é«ã«ãããŠèµ€èœçã®æçè±æ žã«ã
ã€ãŠã€ãããããããšãªã¹ãããšãã³ã¯æªååã®
骚é«å¹¹çŽ°èã«äœçšããŠèµ€è¡çãžã®ååãåŒãèµ·ã
ãå åã§ãããäœçµèã®é žçŽ åå§ãäœäžããŠäœé ž
çŽ ç¶æ ã«ãªããšåæ³ãä¿é²ãããã ããªãã¡ããšãªã¹ãããšãã³ã¯éªšé«ã«ãããŠç
ç£ãããèµ€è¡çæ°ãå¶åŸ¡ããäœæ¶²æ§ãã«ã¢ã³ã§ã
ãã ãã®ãšãªã¹ãããšãã³ã¯ååé27000ã66000çš
床ãšæšå®ãããã·ã¢ãªã³é žãå«ãç³èçœè³ªã§åºä¹³
åç©ã§ã¯ãã®å šéšãŸãã¯å€§éšåãè èã§çç£ãã
ãŠããã 人ã®èµ€è¡çæ°ã®æžå°ããçŸæ£ãããªãã¡ã貧
è¡ãã¯ãã®æå ããã¿ãŠå€§ããïŒã€ã®åã«åãã
ããã第ïŒã®åã¯èµ€è¡çã®çŽ ã«ãªã幹现èã«ç°åžž
ããã€ãŠããšãªã¹ãããšãã³ã®ç£çèœãæ£åžžã§ã
ã€ãŠãèµ€è¡çãäœãããšãã§ããªãå Žåãããªã
ã¡ãåçäžè¯æ§è²§è¡ãã§ããããã®å¹¹çŽ°èã®ç°åžž
ãæŽã«è©³ããåããŠã¿ããªãã°ã骚é«ã®äœåœ¢æå¹¹
现èãã®ãã®ã®ç°åžžãèµ€è¡çã®å¢æ®ããå Žã®äž
å šããšãªã¹ãããšãã³ã«å¯Ÿããåå¿æ§ã®äœäžãªã©
ã§ããããã®çŸæ£ã®å Žåã«ã¯ãçäœã¯èµ€è¡çæ°ã
å¢å ãããããšããæ©æ§ãåããŠãšãªã¹ãããšã
ã³ã¯éåžžã«é«ãå€ãããã¯ç°åžžã«é«ãå€ã瀺ãã
第ïŒã®åã¯æ ¢æ§è äžå šãªã©ã®å Žåã®ãããããè
æ§è²§è¡ãã§ããã®å Žåã幹现èã¯æ£åžžã§ãã€ãŠã
ãšãªã¹ãããšãã³ç£çèåšã§ããè èã«åšè³ªçç
å€ããã€ãŠãšãªã¹ãããšãã³ãçç£ããããšãã§
ããããã®çºèµ€è¡çãå¢å ãã貧è¡ãšãªãããã®
å Žåã¯äœæ¶²äžã«ã¯äœæ¿åºŠã®ãšãªã¹ãããšãã³ãå
åšããã®ã¿ã§ããã第ïŒã®åã¯å¹¹çŽ°èããã³ãšãª
ã¹ãããšãã³ç£çèœãå ±ã«æ£åžžãªå Žåã§ãéæ¬
ä¹ã倱è¡ããã¿ãã³B12æ¬ ä¹ãèªå·±å ç«ã«ãã溶
è¡ãªã©ã«èµ·å ãã貧è¡ã§ããããã®å Žåããšãªã¹
ãããšãã³ã¯é«ãå€ã瀺ãããã¢ã°ããã³éãšè²
ã®çžé¢ã瀺ãã 貧è¡ãã®ãã®ã®èšºæã¯èµ€è¡çå®æ°ã®èšæ°ããã
ãã¯ãããã¯ãªããæ³ã«ããè¡ç容éã®æž¬å®ãã
ã¢ã°ããã³ã®æž¬å®çã«ãã容æã«èšºæããããšã
ã§ãããããã®ç å ã骚é«å¹¹çŽ°èã®ç°åžžã«ããã®
ããè ã®ç å€ã«åºã¥ããšãªã¹ãããšãã³ã®ç£çäž
å šã«ããã®ãããããã¯äž¡è 以å€ã«åå ãããã®
ãã蚺æããããšã¯æ²»çæ¹éã®èšå®ãäºåŸã®äºæž¬
çã«ãšã€ãŠæ¥µããŠéèŠã§ããããŸããã®çºã«ã¯äœ
液äžã®ãšãªã¹ãããšãã³ã®å®éãäžå¯æ¬ ã§ããã
ãšã¯èªæã§ããã åŸæ¥ããšãªã¹ãããšãã³ã®æž¬å®ã«ã¯ãããŠã¹ã
ããã¯ã©ããã«ãããã€ãªã¢ãã»ã€æ³ãåžžçšãã
ãŠãããããªãã¡ãå€è¡ããŠã¹ãããã¯é£¢é€ã©ã
ãã«ãšãªã¹ãããšãã³ã泚å°ããåŸã 59Feã泚
å°ããŠãã® 59Feã®è¡çãžã®å蟌ã¿çãããšãªã¹
ãããšãã³éãèšç®ããæ¹æ³ã§ããããã®æ¹æ³ã¯
ç¹ç°æ§ã«ãããŠåªããŠããããå€æ°ã®åç©ã®é·æ
éã®é£Œè²ãã¢ã€ãœããŒãã®äœ¿çšçã«å ããŠéåžžã«
ææ°ãšçµè²»ãèŠããèšåºæ€æ»ã«å¿çšããããšã¯å®¹
æã§ã¯ãªãããã®ç¹ãèæ ®ããŠãšãªã¹ãããšãã³
ãèµ€è¡çã«æäœããŠãããè©Šæäžã®ãšãªã¹ãããš
ãã³ã§æãšãªã¹ãããšãã³æäœãäžåããŠããã
ã®æäœè¡çã«ããåéæå¶åå¿ã«ããå€å®ããæ¹
æ³ãéçºãããŠãããããããã®æ¹æ³ã§ã¯ã人ã®
è¡æž äžã«å«ãŸããŠããéç¹ç°çèµ€è¡çåéçŽ ãé€
å»ããå¿ èŠãããçºè¡çæäœã®åžååŠçãããªã
ãã°ãªããããŸããã®ç¢ºèªè©Šéšãããã«å¿ èŠãšã
ãã°ããããçç©åŠç掻æ§ãšäžèŽããªãããšãå€
ããä¿¡é Œæ§ã確ç«ãããŠããªãïŒèšåºæ€æ»ç¬¬22å·»
第ïŒå·134ã140é ïŒ1978幎ïŒåç §ïŒãæŽã«ä»ã®æ
ç®ã«ããèµ€è¡çåéé»æ¢åå¿
ïŒHemagglutination inhibitionïŒã¯ãšãªã¹ãããš
ãã³ã®æž¬å®æ¹æ³ãšããŠé©åœã§ãªããšèšèŒãããŠã
ãæ¥æ¬èšåº38å·»ã»æ¥å£å¢åå·ïŒ1980ïŒç¬¬656é
å·Šæ¬17ã26è¡ç®åã³å43å·»ã»ç§å£èšæå¢åå·
ïŒ1985ïŒç¬¬1155é å³æ¬ïŒãïŒè¡ç®åç §ïŒœããŸããäž
è¬ã«ãããžèµ€è¡çã«æåãæäœã§ãããããšãã€
ãŠã該æåãã©ããã¯ã¹ç²åã«æ æã§ãããšã¯é
ããããŸãæ æã§ãããšããŠãè¯å¥œãªçµæãåŸã
ãããšã¯éããªãã æ¬çºæè ãã¯ããããåŸæ¥æ³ã®é£ç¹ã解決ãã
ãšãªã¹ãããšãã³ã容æã«ç¹ç°çã«æ¯èŒççæé
ã§æž¬å®ããæ¹æ³ãéçºãã¹ãéæç 究ãéããçµ
æã粟補ãšãªã¹ãããšãã³ãã©ããã¯ã¹ç²åã«æ
äœããŠãšãªã¹ãããšãã³æäœã©ããã¯ã¹ã補é
ãããããçšããŠè©ŠæãäœãååŠçããããšãªã
äœæ¶²äžã®ãšãªã¹ãããšãã³ãå身ã©ããã¯ã¹åé
æå¶åå¿ã«ãã枬å®ããããšã«æåããæ¬çºæã
å®æããã«è³ã€ãã ããªãã¡ãæ¬çºæã®ç®çã¯ãšãªã¹ãããšãã³æ
äœã©ããã¯ã¹ããã³ãšãªã¹ãããšãã³æäœã©ãã
ã¯ã¹ç²åçµæç©ãæäŸããããšã«ããã 次ã«æ¬çºæãããã«è©³çŽ°ã«èª¬æããã æ¬çºæã®æäœã©ããã¯ã¹ã補é ããããã«çšã
ãã©ããã¯ã¹ã¯ãããªã¹ãã¬ã³ãã«ã«ããã·ã«å
ããªã¹ãã¬ã³ãã¢ããåºãæããã«ã«ããã·ã«å
ããªã¹ãã¬ã³ãããªããã«ãã«ãšã³ãã¹ãã¬ã³â
ãã¿ãžãšã³å ±éåäœãã«ã«ããã·ã«åã¹ãã¬ã³â
ãã¿ãžãšã³å ±éåäœãã¹ãã¬ã³âãžããã«ãã³ãŒ
ã³å ±éåäœãããã«ãã«ãšã³â第äžããã«ã¹ãã¬
ã³å ±éåäœãããªãšã¹ãã«ãããªã¢ã¯ãªã«é žãã
ãªã¡ã¿ã¯ãªã«é žãããªã¢ã¯ãªããããªã«ãã¢ã¯ãª
ããããªã«âãã¿ãžãšã³âã¹ãã¬ã³å ±éåäœãã
ãªé ¢é žããã«ã¢ã¯ãªã¬ãŒããããªããã«ãããªã
ã³ãå¡©åããã«âã¢ã¯ãªã¬ãŒãå ±éåäœçã®åæ
é«ååã©ããã¯ã¹ç²åãããªãã©ããã¯ã¹ã§ã
ããããã«ãããã®åæé«ååã©ããã¯ã¹ç²åã®
è¡šé¢ãéã€ãªã³çé¢æŽ»æ§å€çã§åŠçãããã®ã§ã
ã€ãŠããããäžèšããåæé«ååã©ããã¯ã¹ã®ãª
ãã§ãããªã¹ãã¬ã³ã©ããã¯ã¹ã奜ãŸãããã©ã
ãã¯ã¹ç²åã®ç²åŸã¯ã0.01ã10ÎŒã§ããã奜ãŸã
ãã¯0.1ã1.0ÎŒã§ããããåæè©Šéšçµæã®åçŸæ§
ãè¯ãããããã«ã¯ãç²åŸååžã®å¹ ãçããã®ã
äŸãã°0.2±0.005ÎŒã®ãã®ãæãŸããããŸãã䜿
çšãããã©ããã¯ã¹ç²åã®æ¯éã¯0.9ã1.4ã§ã
ãã ãšãªã¹ãããšãã³ã¯è¡æ¶²ãå°¿çã®äœæ¶²äžã«èŠåº
ããããæ¬çºæã«ãããŠçšãããšãªã¹ãããšãã³
調補çšã®åæãšããŠã¯è¡æ¶²ãå°¿ãšãã«çšããããš
ãã§ããããå°¿ã¯ææ³ç©ã§ãã容æã«å ¥æã§ãã
ããšããç¹ã«é©ããŠããããããã®åæãããšãª
ã¹ãããšãã³ã調補ããæ¹æ³ãšããŠã¯ãããžã€ãŒ
ãã«ã»ãªãã»ãã€ãªããžã«ã«ã»ã±ãã¹ããªãŒã
âJournal of Biological Chemistryâvol252ïŒ
5558ã5564ïŒ1977ïŒã«èšèŒãããŠããããã«ãšã¿
ããŒã«æ²æŸ±ãã¢ã»ãã³æ²æŸ±ãã¿ã³ãã³é žæ²æŸ±ãå¡©
åãªããŠã æ²æŸ±ãç¡«å®å¡©æãã²ã«éãDEAEâ
ã»ã«ãâã¹ã¯ãããã°ã©ããããªã¢ã¯ãªã«ã¢ãã
ã²ã«ã¯ãããã°ã©ããã«ãªãªã³åžç解é¢çãç¥ã
ããŠããããŸãããšãªã¹ãããšãã³ã¯100âïŒ15
åã®å ç±ã«èããã®ã§ã粟補ã«å ç«ã€ãŠå ç±åŠç
ãè¡ãªããä»ã®å€§éšåã®èçœè³ªåã³ç³èçœè³ªãç±
å€æ§ãããŠããããšã«ããéç¹ç°çåå¿ãæãã
ããšãã§ãããæ¬çºæã§çšãããšãªã¹ãããšãã³
ã¯äžèšæ¹æ³ã®ã©ã®ãããªçµåãã«ãã€ãŠåŸããã
ãã®ã§ãçšããããšãã§ãããçŽåºŠãäœããšå¯å
å¿ãèµ·ããããšãããã®ã§ãé«çŽåºŠã§åäžã®èçœ
質æšåã§ããããšãæãŸããããã®ããã«ããŠåŸ
ããã粟補ãšãªã¹ãããšãã³ãæåãšããŠãã€
ã®ããŠãµã®ãã¢ã«ã¢ããçã®æäœç£çèœã®ããå
ç©ã«åžžæ³ã«ãã€ãŠå ç«ããåŸæ¡è¡ããŠæåäžåçš
ã®æäœãåŸãããšãã§ããããã®å Žåã«çšããå
ç©ã¯å€§éã®æäœãåŸããããã°äœãçšããŠãã
ããç¹å®ã®åç©ã«éå®ããããã®ã§ã¯ãªãã 次ã«ãæåãšããŠç²Ÿè£œãšãªã¹ãããšãã³ãã©ã
ãã¯ã¹ç²åã«æäœãããçºã«ã¯ãåœè©²ã©ããã¯ã¹
ç²åãšæåãšãæ°Žãççé£å¡©æ°ŽãPH5.5ã10ã奜
ãŸããã¯PH6.4ã7.6ã®å皮緩è¡æ¶²çã®äžã§ãæ¿åºŠ
0.05ãïŒïŒ ã®ã©ããã¯ã¹ç²åãšæ¿åºŠ50ã
1000miuïŒmlã®æåãšãïŒã40âã«ãããŠ30åã
24æéããããã«æ¹æããªããæ¥è§Šãããããšã«
ãã€ãŠè¡ãªããç·©è¡æ¶²ãšããŠã¯ãäŸãã°ãªã³é žå¡©
ç·©è¡é£å¡©æ°Žãã°ãªã·ã³ç·©è¡é£å¡©æ°Žãªã©ãããæäœ
çµäºåŸã¯æ°Žæ§æº¶åªãäŸãã°ãããç·©è¡æ¶²ã§æŽæµã
ãããšã«ãããã©ããã¯ã¹ç²åã«åžçãããªãæ
åãå®å šã«é€å»ãããããã«ãã®ã©ããã¯ã¹ã¯åž
é液ã«æžæ¿ãããŠã©ããã¯ã¹ç²åã®æåæªæäœéš
åãèçœè³ªã§é£œåããŠãããšããã çšé液ãšããŠã¯ãã°ãªã·ã³ç·©è¡é£å¡©æ°Žããªã³é ž
å¡©ç·©è¡é£å¡©æ°Žçã«çè¡æž ã¢ã«ããã³ïŒä»¥äžBSA
ãšç¥ãïŒçŽ0.1ïŒ ãå ãããã®ãçšãã0.01ã0.5
ïŒ ã®ãããªãŠã ã¢ãžãïŒNaN3ïŒãå ããŠããã ãã®ããã«ããŠåŸãããæäœã©ããã¯ã¹ã¯0.25
ééïŒ çšåºŠã«åžé液ã«æžæ¿ãããç¶æ ã§æ°·å®€ã«ä¿
åããŠãããããåçµä¹Ÿç¥ããŠãããŠããããå
çµä¹Ÿç¥ããçºã«ã¯åžé液ã«å®å®å€ãšããŠåçš®ã¢ã
ãé žé¡ãç¹ã«ã°ãªã·ã³ãã°ã«ã¿ãã³é žãããªãŠã
ããã³ããã¹ãã©ã³ããããã0.2ãïŒééïŒ ã
ãã³0.3ãïŒééïŒ ãå ããŠæ¶²äœçªçŽ ãããã¯æ¶²
äœç©ºæ°äžãªã©ã§æ¥éåçµããŠããåçµä¹Ÿç¥ããã
åçµä¹Ÿç¥ã«ããä¿åæéã¯ããã«å»¶é·ãããéåžž
ïŒå¹Žä»¥äžå®å®ã§ããã æ¬çºæã®ãšãªã¹ãããšãã³æäœã©ããã¯ã¹ã¯æ
ãšãªã¹ãããšãã³æäœã«ããåéãããã®ã§ããŸ
ã人ã®äœæ¶²ãããã¯ãã®åžé液ãšæãšãªã¹ãããš
ãã³æäœãæ¥è§ŠãããŠãšãªã¹ãããšãã³ãååšã
ããªãããã®æåã«ãã€ãŠæäœãäžåããããã
ãåŸãšãªã¹ãããšãã³æäœã©ããã¯ã¹ãæ¥è§Šãã
ããšãäœæ¶²äžãŸãã¯ãã®åžé液äžã«ãšãªã¹ãããš
ãã³ãååšããå Žåã«ã¯æäœã¯äžåãããŠæäœã©
ããã¯ã¹ã¯åéãããéã«äœæ¶²äžã«ãšãªã¹ãããš
ãã³ãååšããªãå Žåã«ã¯ãæäœã¯äžåãããã
ãã®æäœã«ãã€ãŠæäœã©ããã¯ã¹ã¯åéãããã
ã®åå¿ããã€ã¯ãã¿ã€ã¿ãŒæ³ã§è¡ãªãå Žåããã€
ã¯ããã¬ãŒãäžã«ç®¡åºåéåãšããŠèªããããšã
ã§ãããããªãã¡ããã¬ãŒãã«äžå®éã®åžé液ã
滎äžå泚ãã次ãã§ç¬¬ïŒç©Žç®ã«äžå®éã®äœæ¶²ãå
ãããã€ãªãŠãŒã¿ãŒã§é 次åžéãããããã«æãš
ãªã¹ãããšãã³æäœãäžå®é滎äžå泚ããŠäžå®æ
éåå¿ãããŠããæåæäœã©ããã¯ã¹ã滎äžå泚
ããäžå®æéåŸã«ç®¡åºåéåãå€å®ããããã®å Ž
åãæ£ç¢ºã«æ¿åºŠæ¢ç¥ã®æšæºãšãªã¹ãããšãã³ã䜵
çšãããªãã°ããã®æšæºç©è³ªã«ã€ããŠã®åéé»æ¢
å€ããæ¯äŸèšç®ããããšã«ããæªç¥ã®äœæ¶²æ¿åºŠã
èšç®ããããšã容æã§ãããæªç¥äœæ¶²äžã®ãšãªã¹
ãããšãã³ã®æ¿åºŠãæ±ããããšãã§ããã æ¬çºæã®æäœã©ããã¯ã¹ã¯æ¬¡ã®ç¹ã§æ¥µããŠå€§ã
ãªå©ç¹ãæããŠãããããªãã¡ãäœæ¶²äžã«ã¯ã©ã
ãã¯ã¹ãã®ãã®ã«å¯Ÿããéç¹ç°çåéçŽ ãããªã
ã¡æ äœã«å¯Ÿããæäœãå šãååšãããããŸãå®é
ã«çºèŠãããŠããªãã®ã§è¢«æ€äœæ¶²ãäœçååŠçã
ãå¿ èŠããªãããŸããã®çºã®ç¢ºèªè©Šéšãå¿ èŠãšã
ãªãããã€ã¯ããã¬ãŒãã®ãŠãšã«ã«äœæ¶²ãããã¯
ãã®åžé液ãå ¥ããããã«æäœã滎äžããåŸãæ
äœã©ããã¯ã¹ã滎äžããã ãã§ãããããªãã¡ãš
ãªã¹ãããšãã³ã®å®éã¯æ¥µããŠå®¹æãã€ç°¡äŸ¿ã§ã
ããç¹å¥ã®æè¡ãå šãèŠããªãããããæåã粟
補ãããŠããã®ã§æ¥µããŠç¹ç°çã§ããããããæ
床ã¯äººäœæ¶²äžã®æž¬å®ã«å šãäžè¶³ã¯ãªãããåæã«
å€æ°ã®æ€äœã®å®æ§ããã³ãŸãã¯å®éãè¡ãªãããš
ãã§ããã æ¬çºæã®æäœã©ããã¯ã¹ãçšããã°ãåŸæ¥æ¥µã
ãŠè€éãªãã€ãªã¢ãã»ã€æ³ã«é Œã€ãŠããäœæ¶²äžã®
ãšãªã¹ãããšãã³æ¿åºŠãçæéã«å®¹æãã€ç°¡äŸ¿ã«
å®éããããšãã§ãã貧è¡æ£è ã®ç å 解æãæ£ç¢º
ã«è¡ãªãããšãã§ããã»ãæ²»ççµæã®å€å®ãäºåŸ
ã®äºæž¬ãè¡ãªãããšãã§ãããåããšãªã¹ãããš
ãã³ã®å°¿ãªã©ããã®çç£å·¥çšã«ãããæ¿åºŠã®æž¬å®
ã«ãå¿çšã§ããã çŸåšãŸã§ã«ãšãªã¹ãããšãã³ãã©ããã¯ã¹ã«æ
äœããäŸãèšèŒããæç®ã¯å šããªããæåæäœã©
ããã¯ã¹ãçšããåéæå¶åå¿ã¯å šãæ°èŠã§ã
ãã ãŸãããã®æäœã©ããã¯ã¹ã¯æãšãªã¹ãããšã
ã³æäœã«ã®ã¿åå¿ãããã以å€ã®æäœããããã¯
è¡æŒ¿èçœã«å šãåå¿ããªãããšãæªæäœã©ããã¯
ã¹ã¯æãšãªã¹ãããšãã³æäœããã以å€ã®æäœã
è¡æŒ¿èçœã«å šãåå¿ããªãããšããããã®æäœã©
ããã¯ã¹ã¯ãšãªã¹ãããšãã³ãçµåããŠãããã®
ã§ãããšãããã 次ã«æ¬çºæã調補äŸããã³å®æœäŸã«ãã€ãŠãã
ã«è©³çŽ°ã«èª¬æããããæ¬çºæã¯ãã®èŠæšãè¶ ããª
ãéããããã«ãã€ãŠéå®ããããã®ã§ã¯ãªãã èª¿è£œäŸ ïŒ ãšãªã¹ãããšãã³ã®èª¿è£œ 貧è¡æ£è å°¿ã«ããšããŒã«ã0.1ïŒ å ããããã«
ãšãã«ã¢ã«ã³ãŒã«ïŒå®¹ãå ãã氷宀ã«äžå€æŸçœ®ã
ãã3000rpmã§30åéé å¿åé¢ããŠæ²æž£ãéãã
ãããççé£å¡©æ°Žã«æº¶è§£ããççé£å¡©æ°Žã«å¯Ÿãäž
å€éæããããããå°è©Šéšç®¡ã«å泚ãã沞隰氎äž
ã«15åé浞挬ããŠå ç±ããé«éé å¿åé¢ããäžæž
ã«ã€ããŠã«ãªãªã³åžç解é¢æäœããããããªã
ã¡ãççé£å¡©æ°Žã§ïŒåæŽæµããã«ãªãªã³ããã€ã
ã·ã€ãŒç€Ÿè£œãã¢ã·ããã»ãŠãªãã·ãŠãã»ã«ãªãª
ã³ãFisher Scientific CompanyâAcid Washed
Kaolinâãã10ïŒ å ããPHã4.8ã«ããïŒâã§24æ
éãã€ããæ¹æããããã®ã«ãªãªã³ã3000rpmã§
é å¿åé¢ããŠéãPH4.8ã®é ¢é žå¡©ç·©è¡æ¶²ã§æŽæµã
ãåŸã1MïŒNH4OHã«æžæ¿ãããŠïŒæé宀枩ã§
ãã€ããæ¹æãã3000rpmã§30åéé å¿åé¢ããŠ
äžæž ãåé¢ããããã®è§£é¢æäœãïŒåç¹°ãè¿ããŠ
äžæž ãåãããããã®è©Šæã0.029MïŒNaH2PO4
åã³0.029MïŒNaClãå«ã溶液ã«å¯ŸããŠéæã
ãã次ãã§0.029MïŒNaH2PO4åã³0.029MïŒ
NaClãå«ã溶液ã«ãŠå¹³è¡¡åããDEAEâã»ã«ã
ãŒã¹äžã«ãã®è©Šæãå ãã宀枩ã§ïŒæéãã€ãã
æ¹æããŠåžçããã2000rpmã®é å¿ã«ãã€ãŠ
DEAEâã»ã«ããŒã¹ãéããå液ã§ïŒåæŽæµãã
åŸã0.05MïŒNa2HPO4åã³0.15MïŒNaClãå«ã
溶液ã§ïŒå溶åºãè¡ãªã€ãããããã©ã€ããªã²ã«
ïŒLyphogelïŒç»é²åæšïŒïŒç±³åœïŒGelman
Instrument Co.ïŒè£œããªã¢ã¯ãªã«ã¢ããã»ã²ã«
ã®åååïŒã§æ¿çž®ããåŸãã»ãã¢ããã¯ã¹ïŒ§â
100ã§ã²ã«éãã掻æ§éšåãååãããããã
å床ãšã¿ããŒã«æ²æŸ±ããããšã¿ããŒã«ã§æŽæµåŸã
ççé£å¡©æ°Žã«æº¶è§£ããççé£å¡©æ°Žã«å¯ŸããŠéæã
ãŠãšãªã¹ãããšãã³è©Šæãšããã èª¿è£œäŸ ïŒ æãšãªã¹ãããšãã³æäœã®èª¿è£œ äžèšã®èª¿è£œæ³ã®ãã¡ãå ç±åŠçã®ã¿ãé€ããŠèª¿
補ããè©Šæãå ç«çšæåãšããããã®æåããã
ã€ã³ãã»ã³ã³ããªãŒãã»ã¢ãžãŠãã³ã
ïŒFreundâ²s Complete adjuvantïŒãšæ··åããïŒã
ïŒKgã®ãŠãµã®ç®äžã«ïŒæ¥ããã«ïŒå泚å°ããåŸã
çèå ã«ïŒå泚å°ããïŒé±åŸççé£å¡©æ°Žã«æº¶è§£ã
ãè©Šæãéèå ã«æ³šå°ããæåŸã®æ³šå°ããïŒé±é
åŸã«é åèããå šæ¡è¡ãè¡ãªããåžžæ³éãè¡æž ã
é å¿åé¢ãã56âã30åéå ç±ããæãšãªã¹ãã
ãšãã³æäœãšãããããã¯çªåãœãŒãã0.1ïŒ å
ããŠïŒâã«ä¿åãããåŸãããæè¡æž ã¯æåãšãª
ã¯ã¿ãŒããŒããŒæ³ããã³å ç«é»æ°æ³³åæ³ã«ãã€ãŠ
äžæ¬ã®æ²éç·ã®ã¿ã圢æããåäžã®æäœã§ããã
ãšã確èªãããã å®æœäŸ ïŒ ãšãªã¹ãããšãã³æäœã©ããã¯ã¹ã®èª¿è£œ 1/15ïŒçé žå¡©ç·©è¡æ¶²ïŒPH7.2ïŒïŒå®¹ãšççé£å¡©
液ïŒå®¹ãšã®æ··å液ïŒä»¥äžPBSãšç¥ãïŒã«ã©ãã
ã¯ã¹ãæŠç°è¬åå·¥æ¥(æ ª)補ãSDL59ïŒæ¯é1.18ïŒç²
åŸ0.9ÎŒïŒãããã®ç²åæ¿åºŠã0.25ïŒ ã«ãªãããã«
æžæ¿ããããã«ãæŽã«PBSãçšããŠ250miuïŒmilli
immuno chemical unitïŒïŒmlã«ãªãããã«åžé
ãããšãªã¹ãããšãã³ãçéå ãã宀枩ã«ïŒæé
ä¿ã¡ã3000rpmã§10åé å¿åé¢ããŠã©ããã¯ã¹ç²
åãååããPBSã次ãã§åžé液ã§æŽæµããåŸã
åžé液ã«0.25ïŒ ã«ãªãããã«æžæ¿ããŠãšãªã¹ãã
ãšãã³æäœã©ããã¯ã¹ãåŸãããã®æäœã©ããã¯
ã¹ã¯ãæãšãªã¹ãããšãã³æäœãšãã€ã¯ããã¬ãŒ
ãäžã§åéããããæããã¢ã«ããã³ãæãã
IgGãæãããã©ã³ã¹ããšãªã³ãæãããããã°
ããã³ãæããβ2ãã¯ãã°ãããªã³ã®åæäœãå
ããŠãåéããªãã€ãããŸãæãšãªã¹ãããšãã³
æäœã«ãšãªã¹ãããšãã³ãå ããŠäžåããåŸãšãª
ã¹ãããšãã³æäœã©ããã¯ã¹ãå ããŠãåéããª
ãã€ãããŸããšãªã¹ãããšãã³ãæäœããªãã©ã
ãã¯ã¹ã¯åäžã®æ¡ä»¶ã§æãšãªã¹ãããšãã³æäœã
å ããŠãåéããªãã€ããããªãã¡ããã®æäœã©
ããã¯ã¹ã¯æãšãªã¹ãããšãã³ã«ç¹ç°çã«åå¿ã
ãŠåéããããšã確èªã§ããã åžé液ã¯1/60ïŒïŒPH7.2ã®ãªã³é žå¡©ç·©è¡é£å¡©æ°Ž
ã«BSAã0.1ïŒ ã«ãªãããã«å ãããã®ã§ããã å®æœäŸ ïŒ ãšãªã¹ãããšãã³æäœã©ããã¯ã¹ã®åçµä¹Ÿç¥ å®æœäŸïŒã§èª¿è£œããæäœã©ããã¯ã¹ããã°ãªã·
ã³0.5ééïŒ ãããã¹ãã©ã³ïŒŽâ10ã0.7ééïŒ å«
æããåžé液ã«2.5ïŒ ã«æµ®éããã液äœçªçŽ äžã«
浞挬ããŠæ¥éåçµãããŠããåçµä¹Ÿç¥ããã å®æœäŸ ïŒ ãšãªã¹ãããšãã³ã®æž¬å® åãã€ã¯ããã¬ãŒãã®åç©Žã«åžé液ã0.025
mlãã€å泚ãã第ïŒç©Žç®ã«è¡æž ãŸãã¯å°¿ã0.025
mlå ãããä»æ¹ãæšæºãšãªã¹ãããšãã³75miuïŒ
mlãå¥ã®åã®ç¬¬ïŒç©Žç®ã«åãã0.025mlå ããã
ãã€ãªãŠãŒã¿ãŒã§é 次åæ°åžéãããããã«äºã
æšæºãšãªã¹ãããšãã³ã§ïŒç®¡ç®ã«çµæ«ç¹ãããã
ãã«åžéããæãšãªã¹ãããšãã³æäœã0.025ml
ãã€å šéšã®ç©Žã«å泚ããæ··åããã宀枩ã«30åä¿
ã€ãåŸãå®æœäŸïŒã§åŸããããšãªã¹ãããšãã³æ
äœã©ããã¯ã¹ã0.025mlãã€å泚ãããã€ã¯ãã
ããµãŒã§ããæ··åããåŸã宀枩ã«10æé以äžé眮
ããåéæå¶ã®çµæ«ç¹ã枬å®ããæšæºãšãªã¹ãã
ãšãã³ãšæ¯èŒããŠãšãªã¹ãããšãã³æ¿åºŠãèšç®ã
ãã ãã®æ¹æ³ã«ãã€ãŠããè¡æž äžãšãªã¹ãããšãã³
æ¿åºŠã枬å®ããçµæã¯è¡šã®éãã§ãã€ãã
ã«é¢ãããããã«è©³ããã¯ãããã®ç²Ÿè£œãšãªã¹ã
ããšãã³ãæäœããããšãªã¹ãããšãã³æäœã©ã
ãã¯ã¹ç²åãå«æããæäœã©ããã¯ã¹ããã³ãã
ã«å®å®å€ãå«æãããšãªã¹ãããšãã³æäœã©ãã
ã¯ã¹ã«é¢ããã ããã®èµ€è¡çã®å¯¿åœã¯çŽ120æ¥ã§ãããæ¯æ¥å š
èµ€è¡çã®1/120ã现網å ç®ç³»ã§ç Žå£ãããããå
æã«åãæ°ã®èµ€è¡çãç£çãããŠåžžã«äžå®ã®èµ€è¡
çæ°ãä¿ãããŠããã èµ€è¡çã¯ã骚é«ã«ãããŠèµ€èœçã®æçè±æ žã«ã
ã€ãŠã€ãããããããšãªã¹ãããšãã³ã¯æªååã®
骚é«å¹¹çŽ°èã«äœçšããŠèµ€è¡çãžã®ååãåŒãèµ·ã
ãå åã§ãããäœçµèã®é žçŽ åå§ãäœäžããŠäœé ž
çŽ ç¶æ ã«ãªããšåæ³ãä¿é²ãããã ããªãã¡ããšãªã¹ãããšãã³ã¯éªšé«ã«ãããŠç
ç£ãããèµ€è¡çæ°ãå¶åŸ¡ããäœæ¶²æ§ãã«ã¢ã³ã§ã
ãã ãã®ãšãªã¹ãããšãã³ã¯ååé27000ã66000çš
床ãšæšå®ãããã·ã¢ãªã³é žãå«ãç³èçœè³ªã§åºä¹³
åç©ã§ã¯ãã®å šéšãŸãã¯å€§éšåãè èã§çç£ãã
ãŠããã 人ã®èµ€è¡çæ°ã®æžå°ããçŸæ£ãããªãã¡ã貧
è¡ãã¯ãã®æå ããã¿ãŠå€§ããïŒã€ã®åã«åãã
ããã第ïŒã®åã¯èµ€è¡çã®çŽ ã«ãªã幹现èã«ç°åžž
ããã€ãŠããšãªã¹ãããšãã³ã®ç£çèœãæ£åžžã§ã
ã€ãŠãèµ€è¡çãäœãããšãã§ããªãå Žåãããªã
ã¡ãåçäžè¯æ§è²§è¡ãã§ããããã®å¹¹çŽ°èã®ç°åžž
ãæŽã«è©³ããåããŠã¿ããªãã°ã骚é«ã®äœåœ¢æå¹¹
现èãã®ãã®ã®ç°åžžãèµ€è¡çã®å¢æ®ããå Žã®äž
å šããšãªã¹ãããšãã³ã«å¯Ÿããåå¿æ§ã®äœäžãªã©
ã§ããããã®çŸæ£ã®å Žåã«ã¯ãçäœã¯èµ€è¡çæ°ã
å¢å ãããããšããæ©æ§ãåããŠãšãªã¹ãããšã
ã³ã¯éåžžã«é«ãå€ãããã¯ç°åžžã«é«ãå€ã瀺ãã
第ïŒã®åã¯æ ¢æ§è äžå šãªã©ã®å Žåã®ãããããè
æ§è²§è¡ãã§ããã®å Žåã幹现èã¯æ£åžžã§ãã€ãŠã
ãšãªã¹ãããšãã³ç£çèåšã§ããè èã«åšè³ªçç
å€ããã€ãŠãšãªã¹ãããšãã³ãçç£ããããšãã§
ããããã®çºèµ€è¡çãå¢å ãã貧è¡ãšãªãããã®
å Žåã¯äœæ¶²äžã«ã¯äœæ¿åºŠã®ãšãªã¹ãããšãã³ãå
åšããã®ã¿ã§ããã第ïŒã®åã¯å¹¹çŽ°èããã³ãšãª
ã¹ãããšãã³ç£çèœãå ±ã«æ£åžžãªå Žåã§ãéæ¬
ä¹ã倱è¡ããã¿ãã³B12æ¬ ä¹ãèªå·±å ç«ã«ãã溶
è¡ãªã©ã«èµ·å ãã貧è¡ã§ããããã®å Žåããšãªã¹
ãããšãã³ã¯é«ãå€ã瀺ãããã¢ã°ããã³éãšè²
ã®çžé¢ã瀺ãã 貧è¡ãã®ãã®ã®èšºæã¯èµ€è¡çå®æ°ã®èšæ°ããã
ãã¯ãããã¯ãªããæ³ã«ããè¡ç容éã®æž¬å®ãã
ã¢ã°ããã³ã®æž¬å®çã«ãã容æã«èšºæããããšã
ã§ãããããã®ç å ã骚é«å¹¹çŽ°èã®ç°åžžã«ããã®
ããè ã®ç å€ã«åºã¥ããšãªã¹ãããšãã³ã®ç£çäž
å šã«ããã®ãããããã¯äž¡è 以å€ã«åå ãããã®
ãã蚺æããããšã¯æ²»çæ¹éã®èšå®ãäºåŸã®äºæž¬
çã«ãšã€ãŠæ¥µããŠéèŠã§ããããŸããã®çºã«ã¯äœ
液äžã®ãšãªã¹ãããšãã³ã®å®éãäžå¯æ¬ ã§ããã
ãšã¯èªæã§ããã åŸæ¥ããšãªã¹ãããšãã³ã®æž¬å®ã«ã¯ãããŠã¹ã
ããã¯ã©ããã«ãããã€ãªã¢ãã»ã€æ³ãåžžçšãã
ãŠãããããªãã¡ãå€è¡ããŠã¹ãããã¯é£¢é€ã©ã
ãã«ãšãªã¹ãããšãã³ã泚å°ããåŸã 59Feã泚
å°ããŠãã® 59Feã®è¡çãžã®å蟌ã¿çãããšãªã¹
ãããšãã³éãèšç®ããæ¹æ³ã§ããããã®æ¹æ³ã¯
ç¹ç°æ§ã«ãããŠåªããŠããããå€æ°ã®åç©ã®é·æ
éã®é£Œè²ãã¢ã€ãœããŒãã®äœ¿çšçã«å ããŠéåžžã«
ææ°ãšçµè²»ãèŠããèšåºæ€æ»ã«å¿çšããããšã¯å®¹
æã§ã¯ãªãããã®ç¹ãèæ ®ããŠãšãªã¹ãããšãã³
ãèµ€è¡çã«æäœããŠãããè©Šæäžã®ãšãªã¹ãããš
ãã³ã§æãšãªã¹ãããšãã³æäœãäžåããŠããã
ã®æäœè¡çã«ããåéæå¶åå¿ã«ããå€å®ããæ¹
æ³ãéçºãããŠãããããããã®æ¹æ³ã§ã¯ã人ã®
è¡æž äžã«å«ãŸããŠããéç¹ç°çèµ€è¡çåéçŽ ãé€
å»ããå¿ èŠãããçºè¡çæäœã®åžååŠçãããªã
ãã°ãªããããŸããã®ç¢ºèªè©Šéšãããã«å¿ èŠãšã
ãã°ããããçç©åŠç掻æ§ãšäžèŽããªãããšãå€
ããä¿¡é Œæ§ã確ç«ãããŠããªãïŒèšåºæ€æ»ç¬¬22å·»
第ïŒå·134ã140é ïŒ1978幎ïŒåç §ïŒãæŽã«ä»ã®æ
ç®ã«ããèµ€è¡çåéé»æ¢åå¿
ïŒHemagglutination inhibitionïŒã¯ãšãªã¹ãããš
ãã³ã®æž¬å®æ¹æ³ãšããŠé©åœã§ãªããšèšèŒãããŠã
ãæ¥æ¬èšåº38å·»ã»æ¥å£å¢åå·ïŒ1980ïŒç¬¬656é
å·Šæ¬17ã26è¡ç®åã³å43å·»ã»ç§å£èšæå¢åå·
ïŒ1985ïŒç¬¬1155é å³æ¬ïŒãïŒè¡ç®åç §ïŒœããŸããäž
è¬ã«ãããžèµ€è¡çã«æåãæäœã§ãããããšãã€
ãŠã該æåãã©ããã¯ã¹ç²åã«æ æã§ãããšã¯é
ããããŸãæ æã§ãããšããŠãè¯å¥œãªçµæãåŸã
ãããšã¯éããªãã æ¬çºæè ãã¯ããããåŸæ¥æ³ã®é£ç¹ã解決ãã
ãšãªã¹ãããšãã³ã容æã«ç¹ç°çã«æ¯èŒççæé
ã§æž¬å®ããæ¹æ³ãéçºãã¹ãéæç 究ãéããçµ
æã粟補ãšãªã¹ãããšãã³ãã©ããã¯ã¹ç²åã«æ
äœããŠãšãªã¹ãããšãã³æäœã©ããã¯ã¹ã補é
ãããããçšããŠè©ŠæãäœãååŠçããããšãªã
äœæ¶²äžã®ãšãªã¹ãããšãã³ãå身ã©ããã¯ã¹åé
æå¶åå¿ã«ãã枬å®ããããšã«æåããæ¬çºæã
å®æããã«è³ã€ãã ããªãã¡ãæ¬çºæã®ç®çã¯ãšãªã¹ãããšãã³æ
äœã©ããã¯ã¹ããã³ãšãªã¹ãããšãã³æäœã©ãã
ã¯ã¹ç²åçµæç©ãæäŸããããšã«ããã 次ã«æ¬çºæãããã«è©³çŽ°ã«èª¬æããã æ¬çºæã®æäœã©ããã¯ã¹ã補é ããããã«çšã
ãã©ããã¯ã¹ã¯ãããªã¹ãã¬ã³ãã«ã«ããã·ã«å
ããªã¹ãã¬ã³ãã¢ããåºãæããã«ã«ããã·ã«å
ããªã¹ãã¬ã³ãããªããã«ãã«ãšã³ãã¹ãã¬ã³â
ãã¿ãžãšã³å ±éåäœãã«ã«ããã·ã«åã¹ãã¬ã³â
ãã¿ãžãšã³å ±éåäœãã¹ãã¬ã³âãžããã«ãã³ãŒ
ã³å ±éåäœãããã«ãã«ãšã³â第äžããã«ã¹ãã¬
ã³å ±éåäœãããªãšã¹ãã«ãããªã¢ã¯ãªã«é žãã
ãªã¡ã¿ã¯ãªã«é žãããªã¢ã¯ãªããããªã«ãã¢ã¯ãª
ããããªã«âãã¿ãžãšã³âã¹ãã¬ã³å ±éåäœãã
ãªé ¢é žããã«ã¢ã¯ãªã¬ãŒããããªããã«ãããªã
ã³ãå¡©åããã«âã¢ã¯ãªã¬ãŒãå ±éåäœçã®åæ
é«ååã©ããã¯ã¹ç²åãããªãã©ããã¯ã¹ã§ã
ããããã«ãããã®åæé«ååã©ããã¯ã¹ç²åã®
è¡šé¢ãéã€ãªã³çé¢æŽ»æ§å€çã§åŠçãããã®ã§ã
ã€ãŠããããäžèšããåæé«ååã©ããã¯ã¹ã®ãª
ãã§ãããªã¹ãã¬ã³ã©ããã¯ã¹ã奜ãŸãããã©ã
ãã¯ã¹ç²åã®ç²åŸã¯ã0.01ã10ÎŒã§ããã奜ãŸã
ãã¯0.1ã1.0ÎŒã§ããããåæè©Šéšçµæã®åçŸæ§
ãè¯ãããããã«ã¯ãç²åŸååžã®å¹ ãçããã®ã
äŸãã°0.2±0.005ÎŒã®ãã®ãæãŸããããŸãã䜿
çšãããã©ããã¯ã¹ç²åã®æ¯éã¯0.9ã1.4ã§ã
ãã ãšãªã¹ãããšãã³ã¯è¡æ¶²ãå°¿çã®äœæ¶²äžã«èŠåº
ããããæ¬çºæã«ãããŠçšãããšãªã¹ãããšãã³
調補çšã®åæãšããŠã¯è¡æ¶²ãå°¿ãšãã«çšããããš
ãã§ããããå°¿ã¯ææ³ç©ã§ãã容æã«å ¥æã§ãã
ããšããç¹ã«é©ããŠããããããã®åæãããšãª
ã¹ãããšãã³ã調補ããæ¹æ³ãšããŠã¯ãããžã€ãŒ
ãã«ã»ãªãã»ãã€ãªããžã«ã«ã»ã±ãã¹ããªãŒã
âJournal of Biological Chemistryâvol252ïŒ
5558ã5564ïŒ1977ïŒã«èšèŒãããŠããããã«ãšã¿
ããŒã«æ²æŸ±ãã¢ã»ãã³æ²æŸ±ãã¿ã³ãã³é žæ²æŸ±ãå¡©
åãªããŠã æ²æŸ±ãç¡«å®å¡©æãã²ã«éãDEAEâ
ã»ã«ãâã¹ã¯ãããã°ã©ããããªã¢ã¯ãªã«ã¢ãã
ã²ã«ã¯ãããã°ã©ããã«ãªãªã³åžç解é¢çãç¥ã
ããŠããããŸãããšãªã¹ãããšãã³ã¯100âïŒ15
åã®å ç±ã«èããã®ã§ã粟補ã«å ç«ã€ãŠå ç±åŠç
ãè¡ãªããä»ã®å€§éšåã®èçœè³ªåã³ç³èçœè³ªãç±
å€æ§ãããŠããããšã«ããéç¹ç°çåå¿ãæãã
ããšãã§ãããæ¬çºæã§çšãããšãªã¹ãããšãã³
ã¯äžèšæ¹æ³ã®ã©ã®ãããªçµåãã«ãã€ãŠåŸããã
ãã®ã§ãçšããããšãã§ãããçŽåºŠãäœããšå¯å
å¿ãèµ·ããããšãããã®ã§ãé«çŽåºŠã§åäžã®èçœ
質æšåã§ããããšãæãŸããããã®ããã«ããŠåŸ
ããã粟補ãšãªã¹ãããšãã³ãæåãšããŠãã€
ã®ããŠãµã®ãã¢ã«ã¢ããçã®æäœç£çèœã®ããå
ç©ã«åžžæ³ã«ãã€ãŠå ç«ããåŸæ¡è¡ããŠæåäžåçš
ã®æäœãåŸãããšãã§ããããã®å Žåã«çšããå
ç©ã¯å€§éã®æäœãåŸããããã°äœãçšããŠãã
ããç¹å®ã®åç©ã«éå®ããããã®ã§ã¯ãªãã 次ã«ãæåãšããŠç²Ÿè£œãšãªã¹ãããšãã³ãã©ã
ãã¯ã¹ç²åã«æäœãããçºã«ã¯ãåœè©²ã©ããã¯ã¹
ç²åãšæåãšãæ°Žãççé£å¡©æ°ŽãPH5.5ã10ã奜
ãŸããã¯PH6.4ã7.6ã®å皮緩è¡æ¶²çã®äžã§ãæ¿åºŠ
0.05ãïŒïŒ ã®ã©ããã¯ã¹ç²åãšæ¿åºŠ50ã
1000miuïŒmlã®æåãšãïŒã40âã«ãããŠ30åã
24æéããããã«æ¹æããªããæ¥è§Šãããããšã«
ãã€ãŠè¡ãªããç·©è¡æ¶²ãšããŠã¯ãäŸãã°ãªã³é žå¡©
ç·©è¡é£å¡©æ°Žãã°ãªã·ã³ç·©è¡é£å¡©æ°Žãªã©ãããæäœ
çµäºåŸã¯æ°Žæ§æº¶åªãäŸãã°ãããç·©è¡æ¶²ã§æŽæµã
ãããšã«ãããã©ããã¯ã¹ç²åã«åžçãããªãæ
åãå®å šã«é€å»ãããããã«ãã®ã©ããã¯ã¹ã¯åž
é液ã«æžæ¿ãããŠã©ããã¯ã¹ç²åã®æåæªæäœéš
åãèçœè³ªã§é£œåããŠãããšããã çšé液ãšããŠã¯ãã°ãªã·ã³ç·©è¡é£å¡©æ°Žããªã³é ž
å¡©ç·©è¡é£å¡©æ°Žçã«çè¡æž ã¢ã«ããã³ïŒä»¥äžBSA
ãšç¥ãïŒçŽ0.1ïŒ ãå ãããã®ãçšãã0.01ã0.5
ïŒ ã®ãããªãŠã ã¢ãžãïŒNaN3ïŒãå ããŠããã ãã®ããã«ããŠåŸãããæäœã©ããã¯ã¹ã¯0.25
ééïŒ çšåºŠã«åžé液ã«æžæ¿ãããç¶æ ã§æ°·å®€ã«ä¿
åããŠãããããåçµä¹Ÿç¥ããŠãããŠããããå
çµä¹Ÿç¥ããçºã«ã¯åžé液ã«å®å®å€ãšããŠåçš®ã¢ã
ãé žé¡ãç¹ã«ã°ãªã·ã³ãã°ã«ã¿ãã³é žãããªãŠã
ããã³ããã¹ãã©ã³ããããã0.2ãïŒééïŒ ã
ãã³0.3ãïŒééïŒ ãå ããŠæ¶²äœçªçŽ ãããã¯æ¶²
äœç©ºæ°äžãªã©ã§æ¥éåçµããŠããåçµä¹Ÿç¥ããã
åçµä¹Ÿç¥ã«ããä¿åæéã¯ããã«å»¶é·ãããéåžž
ïŒå¹Žä»¥äžå®å®ã§ããã æ¬çºæã®ãšãªã¹ãããšãã³æäœã©ããã¯ã¹ã¯æ
ãšãªã¹ãããšãã³æäœã«ããåéãããã®ã§ããŸ
ã人ã®äœæ¶²ãããã¯ãã®åžé液ãšæãšãªã¹ãããš
ãã³æäœãæ¥è§ŠãããŠãšãªã¹ãããšãã³ãååšã
ããªãããã®æåã«ãã€ãŠæäœãäžåããããã
ãåŸãšãªã¹ãããšãã³æäœã©ããã¯ã¹ãæ¥è§Šãã
ããšãäœæ¶²äžãŸãã¯ãã®åžé液äžã«ãšãªã¹ãããš
ãã³ãååšããå Žåã«ã¯æäœã¯äžåãããŠæäœã©
ããã¯ã¹ã¯åéãããéã«äœæ¶²äžã«ãšãªã¹ãããš
ãã³ãååšããªãå Žåã«ã¯ãæäœã¯äžåãããã
ãã®æäœã«ãã€ãŠæäœã©ããã¯ã¹ã¯åéãããã
ã®åå¿ããã€ã¯ãã¿ã€ã¿ãŒæ³ã§è¡ãªãå Žåããã€
ã¯ããã¬ãŒãäžã«ç®¡åºåéåãšããŠèªããããšã
ã§ãããããªãã¡ããã¬ãŒãã«äžå®éã®åžé液ã
滎äžå泚ãã次ãã§ç¬¬ïŒç©Žç®ã«äžå®éã®äœæ¶²ãå
ãããã€ãªãŠãŒã¿ãŒã§é 次åžéãããããã«æãš
ãªã¹ãããšãã³æäœãäžå®é滎äžå泚ããŠäžå®æ
éåå¿ãããŠããæåæäœã©ããã¯ã¹ã滎äžå泚
ããäžå®æéåŸã«ç®¡åºåéåãå€å®ããããã®å Ž
åãæ£ç¢ºã«æ¿åºŠæ¢ç¥ã®æšæºãšãªã¹ãããšãã³ã䜵
çšãããªãã°ããã®æšæºç©è³ªã«ã€ããŠã®åéé»æ¢
å€ããæ¯äŸèšç®ããããšã«ããæªç¥ã®äœæ¶²æ¿åºŠã
èšç®ããããšã容æã§ãããæªç¥äœæ¶²äžã®ãšãªã¹
ãããšãã³ã®æ¿åºŠãæ±ããããšãã§ããã æ¬çºæã®æäœã©ããã¯ã¹ã¯æ¬¡ã®ç¹ã§æ¥µããŠå€§ã
ãªå©ç¹ãæããŠãããããªãã¡ãäœæ¶²äžã«ã¯ã©ã
ãã¯ã¹ãã®ãã®ã«å¯Ÿããéç¹ç°çåéçŽ ãããªã
ã¡æ äœã«å¯Ÿããæäœãå šãååšãããããŸãå®é
ã«çºèŠãããŠããªãã®ã§è¢«æ€äœæ¶²ãäœçååŠçã
ãå¿ èŠããªãããŸããã®çºã®ç¢ºèªè©Šéšãå¿ èŠãšã
ãªãããã€ã¯ããã¬ãŒãã®ãŠãšã«ã«äœæ¶²ãããã¯
ãã®åžé液ãå ¥ããããã«æäœã滎äžããåŸãæ
äœã©ããã¯ã¹ã滎äžããã ãã§ãããããªãã¡ãš
ãªã¹ãããšãã³ã®å®éã¯æ¥µããŠå®¹æãã€ç°¡äŸ¿ã§ã
ããç¹å¥ã®æè¡ãå šãèŠããªãããããæåã粟
補ãããŠããã®ã§æ¥µããŠç¹ç°çã§ããããããæ
床ã¯äººäœæ¶²äžã®æž¬å®ã«å šãäžè¶³ã¯ãªãããåæã«
å€æ°ã®æ€äœã®å®æ§ããã³ãŸãã¯å®éãè¡ãªãããš
ãã§ããã æ¬çºæã®æäœã©ããã¯ã¹ãçšããã°ãåŸæ¥æ¥µã
ãŠè€éãªãã€ãªã¢ãã»ã€æ³ã«é Œã€ãŠããäœæ¶²äžã®
ãšãªã¹ãããšãã³æ¿åºŠãçæéã«å®¹æãã€ç°¡äŸ¿ã«
å®éããããšãã§ãã貧è¡æ£è ã®ç å 解æãæ£ç¢º
ã«è¡ãªãããšãã§ããã»ãæ²»ççµæã®å€å®ãäºåŸ
ã®äºæž¬ãè¡ãªãããšãã§ãããåããšãªã¹ãããš
ãã³ã®å°¿ãªã©ããã®çç£å·¥çšã«ãããæ¿åºŠã®æž¬å®
ã«ãå¿çšã§ããã çŸåšãŸã§ã«ãšãªã¹ãããšãã³ãã©ããã¯ã¹ã«æ
äœããäŸãèšèŒããæç®ã¯å šããªããæåæäœã©
ããã¯ã¹ãçšããåéæå¶åå¿ã¯å šãæ°èŠã§ã
ãã ãŸãããã®æäœã©ããã¯ã¹ã¯æãšãªã¹ãããšã
ã³æäœã«ã®ã¿åå¿ãããã以å€ã®æäœããããã¯
è¡æŒ¿èçœã«å šãåå¿ããªãããšãæªæäœã©ããã¯
ã¹ã¯æãšãªã¹ãããšãã³æäœããã以å€ã®æäœã
è¡æŒ¿èçœã«å šãåå¿ããªãããšããããã®æäœã©
ããã¯ã¹ã¯ãšãªã¹ãããšãã³ãçµåããŠãããã®
ã§ãããšãããã 次ã«æ¬çºæã調補äŸããã³å®æœäŸã«ãã€ãŠãã
ã«è©³çŽ°ã«èª¬æããããæ¬çºæã¯ãã®èŠæšãè¶ ããª
ãéããããã«ãã€ãŠéå®ããããã®ã§ã¯ãªãã èª¿è£œäŸ ïŒ ãšãªã¹ãããšãã³ã®èª¿è£œ 貧è¡æ£è å°¿ã«ããšããŒã«ã0.1ïŒ å ããããã«
ãšãã«ã¢ã«ã³ãŒã«ïŒå®¹ãå ãã氷宀ã«äžå€æŸçœ®ã
ãã3000rpmã§30åéé å¿åé¢ããŠæ²æž£ãéãã
ãããççé£å¡©æ°Žã«æº¶è§£ããççé£å¡©æ°Žã«å¯Ÿãäž
å€éæããããããå°è©Šéšç®¡ã«å泚ãã沞隰氎äž
ã«15åé浞挬ããŠå ç±ããé«éé å¿åé¢ããäžæž
ã«ã€ããŠã«ãªãªã³åžç解é¢æäœããããããªã
ã¡ãççé£å¡©æ°Žã§ïŒåæŽæµããã«ãªãªã³ããã€ã
ã·ã€ãŒç€Ÿè£œãã¢ã·ããã»ãŠãªãã·ãŠãã»ã«ãªãª
ã³ãFisher Scientific CompanyâAcid Washed
Kaolinâãã10ïŒ å ããPHã4.8ã«ããïŒâã§24æ
éãã€ããæ¹æããããã®ã«ãªãªã³ã3000rpmã§
é å¿åé¢ããŠéãPH4.8ã®é ¢é žå¡©ç·©è¡æ¶²ã§æŽæµã
ãåŸã1MïŒNH4OHã«æžæ¿ãããŠïŒæé宀枩ã§
ãã€ããæ¹æãã3000rpmã§30åéé å¿åé¢ããŠ
äžæž ãåé¢ããããã®è§£é¢æäœãïŒåç¹°ãè¿ããŠ
äžæž ãåãããããã®è©Šæã0.029MïŒNaH2PO4
åã³0.029MïŒNaClãå«ã溶液ã«å¯ŸããŠéæã
ãã次ãã§0.029MïŒNaH2PO4åã³0.029MïŒ
NaClãå«ã溶液ã«ãŠå¹³è¡¡åããDEAEâã»ã«ã
ãŒã¹äžã«ãã®è©Šæãå ãã宀枩ã§ïŒæéãã€ãã
æ¹æããŠåžçããã2000rpmã®é å¿ã«ãã€ãŠ
DEAEâã»ã«ããŒã¹ãéããå液ã§ïŒåæŽæµãã
åŸã0.05MïŒNa2HPO4åã³0.15MïŒNaClãå«ã
溶液ã§ïŒå溶åºãè¡ãªã€ãããããã©ã€ããªã²ã«
ïŒLyphogelïŒç»é²åæšïŒïŒç±³åœïŒGelman
Instrument Co.ïŒè£œããªã¢ã¯ãªã«ã¢ããã»ã²ã«
ã®åååïŒã§æ¿çž®ããåŸãã»ãã¢ããã¯ã¹ïŒ§â
100ã§ã²ã«éãã掻æ§éšåãååãããããã
å床ãšã¿ããŒã«æ²æŸ±ããããšã¿ããŒã«ã§æŽæµåŸã
ççé£å¡©æ°Žã«æº¶è§£ããççé£å¡©æ°Žã«å¯ŸããŠéæã
ãŠãšãªã¹ãããšãã³è©Šæãšããã èª¿è£œäŸ ïŒ æãšãªã¹ãããšãã³æäœã®èª¿è£œ äžèšã®èª¿è£œæ³ã®ãã¡ãå ç±åŠçã®ã¿ãé€ããŠèª¿
補ããè©Šæãå ç«çšæåãšããããã®æåããã
ã€ã³ãã»ã³ã³ããªãŒãã»ã¢ãžãŠãã³ã
ïŒFreundâ²s Complete adjuvantïŒãšæ··åããïŒã
ïŒKgã®ãŠãµã®ç®äžã«ïŒæ¥ããã«ïŒå泚å°ããåŸã
çèå ã«ïŒå泚å°ããïŒé±åŸççé£å¡©æ°Žã«æº¶è§£ã
ãè©Šæãéèå ã«æ³šå°ããæåŸã®æ³šå°ããïŒé±é
åŸã«é åèããå šæ¡è¡ãè¡ãªããåžžæ³éãè¡æž ã
é å¿åé¢ãã56âã30åéå ç±ããæãšãªã¹ãã
ãšãã³æäœãšãããããã¯çªåãœãŒãã0.1ïŒ å
ããŠïŒâã«ä¿åãããåŸãããæè¡æž ã¯æåãšãª
ã¯ã¿ãŒããŒããŒæ³ããã³å ç«é»æ°æ³³åæ³ã«ãã€ãŠ
äžæ¬ã®æ²éç·ã®ã¿ã圢æããåäžã®æäœã§ããã
ãšã確èªãããã å®æœäŸ ïŒ ãšãªã¹ãããšãã³æäœã©ããã¯ã¹ã®èª¿è£œ 1/15ïŒçé žå¡©ç·©è¡æ¶²ïŒPH7.2ïŒïŒå®¹ãšççé£å¡©
液ïŒå®¹ãšã®æ··å液ïŒä»¥äžPBSãšç¥ãïŒã«ã©ãã
ã¯ã¹ãæŠç°è¬åå·¥æ¥(æ ª)補ãSDL59ïŒæ¯é1.18ïŒç²
åŸ0.9ÎŒïŒãããã®ç²åæ¿åºŠã0.25ïŒ ã«ãªãããã«
æžæ¿ããããã«ãæŽã«PBSãçšããŠ250miuïŒmilli
immuno chemical unitïŒïŒmlã«ãªãããã«åžé
ãããšãªã¹ãããšãã³ãçéå ãã宀枩ã«ïŒæé
ä¿ã¡ã3000rpmã§10åé å¿åé¢ããŠã©ããã¯ã¹ç²
åãååããPBSã次ãã§åžé液ã§æŽæµããåŸã
åžé液ã«0.25ïŒ ã«ãªãããã«æžæ¿ããŠãšãªã¹ãã
ãšãã³æäœã©ããã¯ã¹ãåŸãããã®æäœã©ããã¯
ã¹ã¯ãæãšãªã¹ãããšãã³æäœãšãã€ã¯ããã¬ãŒ
ãäžã§åéããããæããã¢ã«ããã³ãæãã
IgGãæãããã©ã³ã¹ããšãªã³ãæãããããã°
ããã³ãæããβ2ãã¯ãã°ãããªã³ã®åæäœãå
ããŠãåéããªãã€ãããŸãæãšãªã¹ãããšãã³
æäœã«ãšãªã¹ãããšãã³ãå ããŠäžåããåŸãšãª
ã¹ãããšãã³æäœã©ããã¯ã¹ãå ããŠãåéããª
ãã€ãããŸããšãªã¹ãããšãã³ãæäœããªãã©ã
ãã¯ã¹ã¯åäžã®æ¡ä»¶ã§æãšãªã¹ãããšãã³æäœã
å ããŠãåéããªãã€ããããªãã¡ããã®æäœã©
ããã¯ã¹ã¯æãšãªã¹ãããšãã³ã«ç¹ç°çã«åå¿ã
ãŠåéããããšã確èªã§ããã åžé液ã¯1/60ïŒïŒPH7.2ã®ãªã³é žå¡©ç·©è¡é£å¡©æ°Ž
ã«BSAã0.1ïŒ ã«ãªãããã«å ãããã®ã§ããã å®æœäŸ ïŒ ãšãªã¹ãããšãã³æäœã©ããã¯ã¹ã®åçµä¹Ÿç¥ å®æœäŸïŒã§èª¿è£œããæäœã©ããã¯ã¹ããã°ãªã·
ã³0.5ééïŒ ãããã¹ãã©ã³ïŒŽâ10ã0.7ééïŒ å«
æããåžé液ã«2.5ïŒ ã«æµ®éããã液äœçªçŽ äžã«
浞挬ããŠæ¥éåçµãããŠããåçµä¹Ÿç¥ããã å®æœäŸ ïŒ ãšãªã¹ãããšãã³ã®æž¬å® åãã€ã¯ããã¬ãŒãã®åç©Žã«åžé液ã0.025
mlãã€å泚ãã第ïŒç©Žç®ã«è¡æž ãŸãã¯å°¿ã0.025
mlå ãããä»æ¹ãæšæºãšãªã¹ãããšãã³75miuïŒ
mlãå¥ã®åã®ç¬¬ïŒç©Žç®ã«åãã0.025mlå ããã
ãã€ãªãŠãŒã¿ãŒã§é 次åæ°åžéãããããã«äºã
æšæºãšãªã¹ãããšãã³ã§ïŒç®¡ç®ã«çµæ«ç¹ãããã
ãã«åžéããæãšãªã¹ãããšãã³æäœã0.025ml
ãã€å šéšã®ç©Žã«å泚ããæ··åããã宀枩ã«30åä¿
ã€ãåŸãå®æœäŸïŒã§åŸããããšãªã¹ãããšãã³æ
äœã©ããã¯ã¹ã0.025mlãã€å泚ãããã€ã¯ãã
ããµãŒã§ããæ··åããåŸã宀枩ã«10æé以äžé眮
ããåéæå¶ã®çµæ«ç¹ã枬å®ããæšæºãšãªã¹ãã
ãšãã³ãšæ¯èŒããŠãšãªã¹ãããšãã³æ¿åºŠãèšç®ã
ãã ãã®æ¹æ³ã«ãã€ãŠããè¡æž äžãšãªã¹ãããšãã³
æ¿åºŠã枬å®ããçµæã¯è¡šã®éãã§ãã€ãã
ãè¡šã
ãè¡šã
å®æœäŸ ïŒ
å®æœäŸïŒã§åŸããããšãªã¹ãããšãã³æäœã©ã
ãã¯ã¹ã«ã©ããã¯ã¹ç²åã0.25ïŒ ã«ãªãããã«åž
é液ãå ããåŸå®æœäŸïŒãšåæ§ã«æäœããŠè¡æž äž
ããã³å°¿äžãšãªã¹ãããšãã³ã枬å®ãããããã®
çµæã¯åæ§ã§ãã€ãã 以äžã®çµæããæãããªåŠããè¡äžãšãªã¹ãã
ãšãã³ã¯éæ¬ ä¹æ§è²§è¡ã§é«å€ãåçäžè¯æ§è²§è¡ã§
ç°åžžé«å€ã瀺ããã®ã«å¯Ÿããè æ§è²§è¡ã§ã¯ç°åžžäœ
å€ã瀺ãããããªãã¡ã貧è¡æ£è ã®ãšãªã¹ãããš
ãã³æ¿åºŠã枬å®ããããšã¯è²§è¡ã®æå ã®èšºæã«æ¥µ
ããŠæçšã§ãããšãããããŸãç å€ã®çšåºŠãç¥ã
ããšã«ãå¿çšã§ããã æ¬çºæã®æäœã©ããã¯ã¹ãçšããã°0.025mlçš
床ã®åŸ®éã®è©Šæã§ããããäœã®ååŠçãèŠããã«
極ããŠå®¹æã«ãšãªã¹ãããšãã³ãå®éããããšã
ã§ãããã®çµæãçç©åŠç掻æ§ãšäžèŽããã®ã§èš
åºèšºæã«ç¹ã«é©ããŠãããšäºããã
ãã¯ã¹ã«ã©ããã¯ã¹ç²åã0.25ïŒ ã«ãªãããã«åž
é液ãå ããåŸå®æœäŸïŒãšåæ§ã«æäœããŠè¡æž äž
ããã³å°¿äžãšãªã¹ãããšãã³ã枬å®ãããããã®
çµæã¯åæ§ã§ãã€ãã 以äžã®çµæããæãããªåŠããè¡äžãšãªã¹ãã
ãšãã³ã¯éæ¬ ä¹æ§è²§è¡ã§é«å€ãåçäžè¯æ§è²§è¡ã§
ç°åžžé«å€ã瀺ããã®ã«å¯Ÿããè æ§è²§è¡ã§ã¯ç°åžžäœ
å€ã瀺ãããããªãã¡ã貧è¡æ£è ã®ãšãªã¹ãããš
ãã³æ¿åºŠã枬å®ããããšã¯è²§è¡ã®æå ã®èšºæã«æ¥µ
ããŠæçšã§ãããšãããããŸãç å€ã®çšåºŠãç¥ã
ããšã«ãå¿çšã§ããã æ¬çºæã®æäœã©ããã¯ã¹ãçšããã°0.025mlçš
床ã®åŸ®éã®è©Šæã§ããããäœã®ååŠçãèŠããã«
極ããŠå®¹æã«ãšãªã¹ãããšãã³ãå®éããããšã
ã§ãããã®çµæãçç©åŠç掻æ§ãšäžèŽããã®ã§èš
åºèšºæã«ç¹ã«é©ããŠãããšäºããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ è¡šé¢ã«å ç±åŠçãããããšãªã¹ãããšãã³ã
æ æããã©ããã¯ã¹ç²åãå«æãããããšãªã¹ã
ããšãã³å®éçšãšãªã¹ãããšãã³æäœã©ããã¯
ã¹ã ïŒ ã©ããã¯ã¹ç²åãå¹³åç²åŸ0.01ã10ÎŒã®ã©ã
ãã¯ã¹ç²åã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ
äœã©ããã¯ã¹ã ïŒ ã©ããã¯ã¹ç²åã®æ¯éã0.9ã1.4ã§ããç¹èš±
è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æäœã©ããã¯ã¹ã ïŒ è¡šé¢ã«å ç±åŠçãããããšãªã¹ãããšãã³ã
æ æããã©ããã¯ã¹ç²åãå«æããã©ããã¯ã¹ã«
ããã«å®å®å€ãå ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒ
ã®æäœã©ããã¯ã¹ã ïŒ å®å®å€ãã°ãªã·ã³ããã³ããã¹ãã©ã³ã§ãã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æäœã©ããã¯ã¹ã ïŒ åžé液ã«å¯Ÿããã°ãªã·ã³ããã³ããã¹ãã©ã³
ã®æ¿åºŠã0.2ãïŒééïŒ ããã³0.3ãïŒééïŒ ã§ã
ãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æäœã©ããã¯ã¹ã
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8074179A JPS566161A (en) | 1979-06-28 | 1979-06-28 | Erythropoietin sensitized latex |
| US06/162,897 US4321058A (en) | 1979-06-28 | 1980-06-25 | Latex composition and method for determining erythropoietin |
| GB8021105A GB2053469B (en) | 1979-06-28 | 1980-06-27 | Composition for determining human erythropoietin its preparation and use |
| DE3024270A DE3024270C2 (de) | 1979-06-28 | 1980-06-27 | Zusammensetzung zur Bestimmung des menschlichen Erythropoietins und Verfahren zu dessen Bestimmung |
| FR8014338A FR2460482A1 (fr) | 1979-06-28 | 1980-06-27 | Composition et procede de titrage de l'erythropoietine humaine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8074179A JPS566161A (en) | 1979-06-28 | 1979-06-28 | Erythropoietin sensitized latex |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS566161A JPS566161A (en) | 1981-01-22 |
| JPS6333103B2 true JPS6333103B2 (ja) | 1988-07-04 |
Family
ID=13726814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8074179A Granted JPS566161A (en) | 1979-06-28 | 1979-06-28 | Erythropoietin sensitized latex |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4321058A (ja) |
| JP (1) | JPS566161A (ja) |
| DE (1) | DE3024270C2 (ja) |
| FR (1) | FR2460482A1 (ja) |
| GB (1) | GB2053469B (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4158785A (en) * | 1984-03-26 | 1985-11-01 | International Health Services | A method of determining the clotting time of blood and particulate reagents therefor |
| JPS61198062A (ja) * | 1985-02-28 | 1986-09-02 | Toyobo Co Ltd | ãšãªã¹ããã€ãšãã³ã®é µçŽ å ç«æž¬å®æ³ |
| IT1204775B (it) * | 1986-01-31 | 1989-03-10 | Rosella Silvestrini | Kit per la determinazione dell'attivita' proliferativa nei tumori umani |
| EP0849595B1 (de) * | 1996-12-18 | 2001-05-09 | Stiftung FÃŒr Diagnostische Forschung | Synthetische Partikel als Agglutinationsreagenzien |
| ES2199058B1 (es) * | 2002-06-06 | 2005-02-16 | Universidad De Malaga | Reactivo de latex para la deteccion de anticuerpos frente a micoplasmaneumoniae. |
| ES2237272B1 (es) * | 2003-03-21 | 2006-07-16 | Universidad De Malaga | Reactivo de latex para la deteccion de anticuerpos frente a legionella pneumophila. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3088875A (en) * | 1959-10-27 | 1963-05-07 | Hyland Lab | Immunological diagnostics utilizing polystyrene latex particles of 0.15 to 0.25 micron |
| NL125235C (ja) * | 1965-04-15 | |||
| GB1384399A (en) * | 1971-02-01 | 1975-02-19 | Hoffmann La Roche | Automated method of obtaining serological data |
| JPS5247012B2 (ja) * | 1974-11-16 | 1977-11-29 | ||
| US4136161A (en) * | 1976-03-16 | 1979-01-23 | Ortho Diagnostics, Inc. | Stabilized erythrocytes and methods therefor |
| US4254095A (en) * | 1978-04-27 | 1981-03-03 | Research Corporation | Radioimmunoassay for erythropoietin |
-
1979
- 1979-06-28 JP JP8074179A patent/JPS566161A/ja active Granted
-
1980
- 1980-06-25 US US06/162,897 patent/US4321058A/en not_active Expired - Lifetime
- 1980-06-27 FR FR8014338A patent/FR2460482A1/fr active Granted
- 1980-06-27 GB GB8021105A patent/GB2053469B/en not_active Expired
- 1980-06-27 DE DE3024270A patent/DE3024270C2/de not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR2460482A1 (fr) | 1981-01-23 |
| GB2053469B (en) | 1983-08-10 |
| FR2460482B1 (ja) | 1984-01-06 |
| JPS566161A (en) | 1981-01-22 |
| DE3024270A1 (de) | 1981-01-22 |
| US4321058A (en) | 1982-03-23 |
| GB2053469A (en) | 1981-02-04 |
| DE3024270C2 (de) | 1984-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wagner et al. | Radioimmunoassay for anaphylatoxins: a sensitive method for determining complement activation products in biological fluids | |
| JPS6243138B2 (ja) | ||
| US4233286A (en) | Low affinity IGM-latex particles and assay therewith for immune complexes | |
| EP0124320B1 (en) | Reagent for detecting antigen | |
| JPS6333103B2 (ja) | ||
| SU1431662A3 (ru) | СпПÑПб пПлÑÑеМО ÑеагеМÑа Ўл пÑПвеЎеМО ÑеакÑОО агглÑÑОМаÑОО | |
| Wu et al. | Highly sensitive method for the assay of plasminogen | |
| GB2030294A (en) | Composition for determination of human beta 2-microglobulin, process for its preparation and its use | |
| JPS5935144A (ja) | è 糞çäœåºåºèæåæäœã©ããã¯ã¹ | |
| JPH0445784B2 (ja) | ||
| JPH08193999A (ja) | å ç«æž¬å®æ³ | |
| JP3542227B2 (ja) | å ç«è©Šè¬ | |
| JP3444649B2 (ja) | å ç«æž¬å®çšè©Šè¬ããã³ãã®è£œé æ¹æ³ | |
| JP3542245B2 (ja) | ç³å°¿ç ãããã¯ç³å°¿ç å䜵ççšããŒã«ãŒãšããŠã®äœ¿çšããã³å ç«è©Šè¬ | |
| JPS5926065A (ja) | ããå°¿ã«ãªã¯ã¬ã€ã³æž¬å®çšè©Šè¬ | |
| JP3542240B2 (ja) | éæã¢ããã€ããŒã·ã¹çšããŒã«ãŒãšããŠã®äœ¿çšããã³éæã¢ããã€ããŒã·ã¹çšå ç«è©Šè¬ | |
| JPS6385358A (ja) | è¡äžéé¢åããªãšâããµã€ããã³ã®é µçŽ å ç«æž¬å®æ³ | |
| JP3512545B2 (ja) | ãã¢ã°ããã³ïœïŒïœã®æž¬å®æ¹æ³ | |
| JP3418429B2 (ja) | éé¢åãªã¬ã³ã枬å®æ³ | |
| JPS60227169A (ja) | çµæ žèãªã³è質æäœæäœã©ããã¯ã¹åã³ãããçšããçµæ žèãªã³è質ã®æ€åºæ¹æ³ | |
| JPS63298061A (ja) | ããïœåå¿æ§ã¿ã³ãã¯ã®å®éæ³ | |
| JPS60224066A (ja) | æããã©ã¯ãããšãªã³æäœæäœã©ããã¯ã¹åã³ãããçšããããã©ã¯ãããšãªã³ã®æ€åºæ¹æ³ | |
| JPH0313863A (ja) | å ç«åŠçã©ããã¯ã¹åéåå¿ããã¡ããç³äŸ¿äžã®Î±ïŒâã¢ã³ãããªãã·ã³ã®æž¬å®æ¹æ³ããã³è©²æ¹æ³ã«äœ¿çšããè©Šè¬ | |
| JPS60364A (ja) | æ°èŠãªæåå®éæ³ | |
| JPS62174659A (ja) | æã¬ãžãªãã©èå€ç³äœæäœæäœã©ããã¯ã¹ |